Gore Rachel H, Bridges John F P, Cohen Julie S, Biesecker Barbara B
Social and Behavioral Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
Department of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, OH, USA.
J Genet Couns. 2019 Dec;28(6):1189-1197. doi: 10.1002/jgc4.1171. Epub 2019 Sep 25.
As exome sequencing expands as a diagnostic tool, patients and providers have voiced concerns about communicating the breadth and scope of potential results when obtaining informed consent. This study aimed to understand how genetic counselors prioritize essential components of the informed consent process and whether counselor factors influence these decisions. Development of a best-worst scaling experiment was informed by a systematic literature review and two focus groups. In all, 11 choice sets were created using a balanced incomplete block design, where participants selected the most and least important object in each set. Mean best-worst (BW) scores were calculated to summarize the relative importance of each object, and mediation analyses assessed whether responses were associated with genetic counselor factors and attitudes. In all, 342 members of the National Society of Genetic Counselors completed the online survey. Ranking of BW scores suggests that participants prioritize collaborative decision-making, assessing understanding and managing expectations, with the least emphasis placed on discussing technological complexities. Stratified analyses found that counselors more experienced with obtaining informed consent for exome sequencing and those reporting higher perceptions of patients' ability to manage information rated discussing variants of uncertain significance as significantly more important (p < .05). Our results suggest that genetic counselors report intentions to prioritize individual patient needs when obtaining informed consent for exome sequencing. Professional characteristics and attitudes may influence preemptive discussion of uncertain results.
随着外显子组测序作为一种诊断工具的应用不断扩大,患者和医疗服务提供者在获取知情同意时,对传达潜在结果的广度和范围表达了担忧。本研究旨在了解遗传咨询师如何确定知情同意过程中关键要素的优先级,以及咨询师的因素是否会影响这些决策。通过系统的文献综述和两个焦点小组,设计了一项最佳-最差尺度实验。总共使用平衡不完全区组设计创建了11个选择集,参与者在每个选择集中选出最重要和最不重要的项目。计算最佳-最差(BW)得分的平均值,以总结每个项目的相对重要性,并通过中介分析评估回答是否与遗传咨询师的因素和态度相关。共有342名美国国家遗传咨询师协会成员完成了在线调查。BW得分的排名表明,参与者将共同决策、评估理解和管理期望列为优先事项,而对讨论技术复杂性的重视程度最低。分层分析发现,在外显子组测序知情同意方面经验更丰富的咨询师,以及那些认为患者处理信息能力较强的咨询师,认为讨论意义不明确的变异更为重要(p <.05)。我们的结果表明,遗传咨询师表示在获取外显子组测序知情同意时,有意优先考虑个体患者的需求。专业特征和态度可能会影响对不确定结果的预先讨论。